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OBJECTIVES We sought to determine whether inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase with pravastatin affects transforming growth factor-beta1 (TGF-
beta1) circulating levels and its production in the monocytes of hypercholesterolemic patients.
BACKGROUND Transforming growth factor-beta1 is a multifunctional growth factor/cytokine involved in
many physiologic and pathologic processes, such as vascular remodeling and atherogenesis.
Statins have been reported to have a modulatory role in cytokine expression in the monocytes
of hyperlipidemic patients.
METHODS We evaluated, in a cross-over study design, plasma TGF-beta1 levels and ex vivo TGF-beta1
production in the monocytes of hypercholesterolemic patients before and after four to six
weeks of lipid-lowering treatment with diet or diet plus 40 mg/day of pravastatin. In addition,
isolated blood monocytes were subjected to pravastatin treatment and evaluated for TGF-
beta1 messenger ribonucleic acid (mRNA) expression and TGF-beta1 in vitro production.
RESULTS Lipid-lowering treatment significantly decreased total cholesterol and low-density lipoprotein
cholesterol plasma levels. Pravastatin, but not a low lipid diet, induced a significant increase
in TGF-beta1 plasma levels (from 1.7  0.5 ng/ml to 3.1  1.1 ng/ml, p  0.001) and in
ex vivo monocyte production (from 1.8  0.8 ng/ml to 3.9  1.0 ng/ml, p  0.001). The
increase in TGF-beta1 levels was not related to the changes in the lipid profile observed with
pravastatin. An increase of approximately twofold in TGF-beta1 production and in mRNA
expression was also observed after in vitro treatment of human monocytes with pravastatin
(5 M). Co-incubation with mevalonate reversed the in vitro effect of pravastatin.
CONCLUSIONS 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibition with pravastatin increases
TGF-beta1 plasma levels, as well as monocyte production, in hypercholesterolemic patients.
The mevalonate pathway plays a role in the regulation of TGF-beta1 expression in human
monocytes. A possible implication in the biologic and clinical effects of statins can be
suggested. (J Am Coll Cardiol 2002;39:1752–7) © 2002 by the American College of
Cardiology Foundation
Transforming growth factor-beta (TGF-beta) is a multi-
functional growth factor peptide reported to be involved in
many physiologic and pathologic processes, such as vascular
remodeling and atherogenesis (1–5). Virtually every cell in
the body, including epithelial, endothelial, hematopoietic
and connective tissue cells, produces TGF-beta and has
receptors for it (1,2). Recent studies support the role of
TGF-beta in the development of human atherosclerotic
lesions (6–11) and in the relationship between atheroscle-
rosis, coagulation and fibrinolysis (12). Physiologic levels of
TGF-beta1 have been measured in the plasma of normal
human subjects, and a possible endocrine role for this
peptide has been suggested (13–15). Conflicting results
have been found regarding circulating levels of TGF-beta1
in patients with atherosclerotic lesions. Grainger et al. (16)
found a severely depressed serum concentration of TGF-
beta1 in patients with advanced atherosclerotic lesions, as
compared with patients with normal coronary arteries. In
contrast, other studies have shown increased levels of
TGF-beta, with both the occurrence and severity of athero-
sclerotic disease (17,18). 3-Hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reductase inhibitors are widely
used to suppress plasma low-density lipoprotein (LDL)
cholesterol levels in patients with primary hypercholesterol-
emia and have demonstrated a benefit in the progression of
atherosclerosis and in the control of cardiovascular events
(19). 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase
inhibitors have been used to establish the functional in-
volvement of the mevalonate pathway in the regulation of
vascular smooth muscle cell proliferation (20), endothelial
function (21), leukocyte-endothelial cell adhesion (22) and
mononuclear cytokine production (23,24). Although there
have been many products elaborated by monocytes and ma-
crophages, no data have been found, at this time, on the effect
of HMG-CoA reductase inhibitors on TGF-beta1, despite the
fact this cytokine is synthesized by these cells, which are within
the major cellular sources of TGF-beta1 (1,2).
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In this study, we conducted a four- to six-week cross-over
study of pravastatin (40 mg/day) and a lipid-lowering diet.
Before and at the end of treatment, the lipid profile and
TGF-beta1 plasma levels were measured. In addition, we
evaluated the effect of lipid-lowering treatment on TGF-
beta1 production and messenger ribonucleic acid (mRNA)
expression in human monocytes cultures. Our results show
that four to six weeks of pravastatin treatment significantly
increased TGF-beta1 circulating levels and its production in
the monocytes of hypercholesterolemic patients. Further-
more, pravastatin induced an increase in mRNA expression
and a dose-dependent increase in TGF-beta1 production in
in vitro cultures of human monocytes. It would appear, from
our observations, that pravastatin has a modulatory role on
the TGF-beta1 profile.
METHODS
Subjects and study design. A total of 18 patients were
enrolled from the Department of Internal Medicine at the
University of Chieti, Italy. Patients with primary hyperlip-
idemia, with no previous history of ischemic heart disease,
were selected. Patients with secondary hyperlipidemia (i.e.,
hypothyroidism, nephrotic syndrome, diabetes) were ex-
cluded. Noncardiovascular conditions associated with a
possible pathogenetic role for TGF-beta (i.e., malignancy,
acute and chronic liver disease, connective tissue disease)
were excluded after a complete medical and laboratory
examination.
The study had a randomized, cross-over design. Hyper-
cholesterolemic patients were randomly allocated to receive
a low-lipid dietary regimen (American Heart Association
[AHA] phase 1 diet) (25) or diet plus pravastatin (40 mg)
for four to six weeks, followed by four to six weeks of
cross-over treatment with a three-week washout period
between regimens. Follow-up clinic visits were scheduled
every four to six weeks to monitor biochemical measures.
The study was approved by the Ethics Committee of Chieti
University, and all patients gave written, informed consent.
Serum total cholesterol, triglyceride and high-density li-
poprotein (HDL) cholesterol concentrations were deter-
mined by conventional enzymatic methods, whereas LDL
cholesterol was calculated by using the Friedewald formula
(26).
TGF-beta1 plasma assay. Drawing blood and preparing
plasma were designed to minimize platelet degranulation
(27). A TGF-beta1 specific enzyme-linked immunosorbent
assay (R & D Systems Europe, Ltd., Abington, UK) was
then used to quantify TGF-beta1 according to the manu-
facturer’s instructions. This assay detects all forms of TGF-
beta1, which can be activated by treatment with acid and
urea, including lipoprotein-associated TGF-beta1 (28). The
sensitivity of this assay was 32 pg/ml; the intra-assay and
inter-assay coefficient of variation were 5.3% and 8.8%,
respectively.
Mink-lung epithelial cell deoxyribonucleic acid (DNA)
synthesis bioassay. Plasma levels and monocyte production
of TGF-beta1 were also quantified by using an assay
measuring the inhibition of the growth of CCL-64 mink-
lung epithelial cells (ATCC, Rockville, Maryland), as pre-
viously described (29). Briefly, CCL-64 cells were plated in
Dulbecco’s modified Eagle’s medium (4  104 cells/ml),
and aliquots of acid-activated plasma samples, a conditioned
medium of cultures of peripheral blood monocytes and
standards of known concentrations of purified platelet
human TGF-beta1 were added in triplicate to the mono-
layers. Synthesis of DNA was determined by pulsing with
0.5 Ci of 3H-thymidine (2 Ci/ml; Amersham Pharmacia
Biotech, Cologno Monzese, Michigan) for an additional
4 h. The TGF-beta1 concentration was determined at a
linear portion of the standard curve.
Isolation of blood monocytes and cell cultures and
TGF-beta1 expression and production. Peripheral blood
monocytes of hypercholesterolemic patients were isolated,
and TGF-beta1 mRNA and the protein secretion rate from
these cells were studied. Peripheral heparinized blood was
diluted 1:1 with normal saline, and mononuclear cells were
separated by the Ficoll-Hypaque gradient, as previously
described (29). Mononuclear cells recovered at the interface
were seeded into Petri dishes, and then adherent monocytes
(1  106 cells/ml) were incubated at 37°C in a 5%
CO2-humidified atmosphere for 24 h in Roswell Park
Memorial Institute with 1% fetal calf serum without and in
the presence of pravastatin alone (1 to 10 M) and
pravastatin plus mevalonate (100 M). After an incubation
time of 24 h, monocyte supernatants were harvested and
kept at 20°C until use.
Northern blot analysis. Ribonucleic acid was purified from
cultured adherent monocytes by a modification of the
guanidine hydrochloride extraction method (30). Total
RNA was fractionated on 1% formaldehyde agarose gel,
transferred to nylon membranes and hybridized according
to the standard procedure. The probe used was a human
TGF-beta1 isoform (gift of Dr. M. L. McGeidy, Labora-
tory of Tumor Immunology and Biology, National Cancer
Institute, Bethesda, Maryland). The size of the transcript
was indicated as relative to 18S and 28S ribosomal RNA,
which were assumed to be 1.8 kb and 5.4 kb, respectively.
A densitometer (Ultrascan XL, Pharmacia, Uppsala,
Sweden) was used for normalization. The autoradiograms
were scanned, and peak areas were measured for relative
mRNA levels (TGF-beta1 mRNA/glyceraldehyde-3-
phosphate dehydrogenase) in the samples tested.
Abbreviations and Acronyms
AHA  American Heart Association
DNA  deoxyribonucleic acid
HDL  high-density lipoprotein
HMG-CoA  3-hydroxy-3-methyl-glutaryl coenzyme A
LDL  low-density lipoprotein
mRNA  messenger ribonucleic acid
TGF-beta1  transforming growth factor-beta1
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Statistical analysis. After testing the data for normality,
we used the Student paired t test to compare biochemical
values at baseline and after each treatment. The baseline
value after the washout period was not different from the
first baseline value, and no carryover effect was present after
each treatment. Multivariate analysis of variance adjusted
for age, gender and changes in lipids as co-variates was
performed to evaluate TGF-beta1 changes after treatment.
The correlation between TGF-beta1 plasma levels and other
biochemical variables was assessed by the Pearson correla-
tion test. A comparison between ex vivo TGF-beta1 pro-
duction in monocytes was made using the nonparametric
Mann-Whitney U test. All in vitro experiments were
conducted in triplicate, with individual preparations of
monocytes. Comparisons among in vitro treatment condi-
tions were carried out by analysis of variance, followed by
Dunnett’s test. The results are expressed as the mean value
 SD. Statistical significance was set at p  0.05. All
computations were carried out using the SAS statistical
package (SAS Institute, Cary, North Carolina) (31).
RESULTS
The salient characteristics of the participants in this study
are as follows: age, 59  11 years; male/female ratio, 7/11;
and body mass index, 24.5  3 kg/m2. As shown in the
Table 1, there was a significant reduction in total and LDL
cholesterol with diet and diet plus pravastatin treatment.
There were no significant effects on triglyceride and HDL
cholesterol levels. As shown in Figure 1, pravastatin treat-
ment resulted in a significant increase in TGF-beta1 levels
(1.7  0.5 ng/ml to 3.1  1.1 ng/ml, p  0.001). There
were no significant differences in the mean values of
TGF-beta1 from baseline to the end of treatment in the
patients treated only with diet (1.7 0.5 ng/ml to 1.6 0.7
ng/ml, p  0.8). The TGF-beta1–dependent biologic
activity was also tested using the mink-lung cells growth
inhibition bioassay, which showed that plasma samples
from hypercholesterolemic patients inhibited DNA synthe-
sis to 48  8% of the control values (CCL-64 cells in the
conditioned medium) (6,400 to 3,100 cpm/well, which was
1.8  0.8 ng/ml on the standard curve); the plasma samples
of patients treated with pravastatin showed an increased
TGF-beta1–dependent inhibitory activity, which came
close to 11.0  0.9% of the control values (6,400 to 700
cpm/well, which was 3.9  1.0 ng/ml on the standard
curve).
Univariate analysis showed, at baseline, no significant
correlation between TGF-beta1 levels, total cholesterol and
LDL cholesterol (Fig. 2). No significant association was
also found between TGF-beta1 levels, triglyceride levels
(r  0.31, p  0.19) and HDL cholesterol levels (r 
0.17, p 0.47).
On multivariate analysis of variance, with age, gender and
Table 1. Effect of Lipid-Lowering Treatment on Lipid Profile
Baseline
Randomized Treatment
Diet
Diet Plus
Pravastatin
Total cholesterol (mg/dl) 263  21 234  22* 206  17†
LDL cholesterol (mg/dl) 175  25 155  18* 127  25†‡
HDL cholesterol (mg/dl) 52  11 52  11 55  12
Triglycerides (mg/dl) 149  38 148  43 129  25
*p  0.01 and †p  0.001 compared with baseline. ‡p  0.01 for pravastatin versus
diet treatment. Data are expressed as the mean value  SD.
HDL and LDL  high- and low-density lipoprotein, respectively.
Figure 1. Scatterplot showing transforming growth factor-beta1 (TGF-
beta1) plasma levels in hypercholesterolemic patients (n  18) before
treatment (baseline) and after diet plus pravastatin (40 mg/day) or diet
alone for four to six weeks.
Figure 2. Scatterplots showing the relationships between transforming
growth factor-beta1 (TGF-beta1) plasma levels and low-density lipoprotein
(LDL) (top) and total cholesterol (bottom) levels in hypercholesterolemic
patients (n  18).
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the magnitude of change in total cholesterol, LDL choles-
terol, triglyceride and HDL cholesterol levels as co-variates,
TGF-beta1 levels were still significantly increased by prav-
astatin (p  0.0001), but not by diet (p  0.50; difference
between therapies: p  0.0006).
In the total cohort, no significant correlation was ob-
served between the magnitude of changes in TGF-beta1
levels and the magnitude of changes in total and LDL
cholesterol after pravastatin treatment (r  0.18, p  0.45
and r 0.87, p 0.72, respectively), and this confirms that
the increase in TGF-beta1 levels after pravastatin therapy
was independent of lipids changes.
Moreover, in a subgroup of nine patients, we evaluated
whether four to six weeks of lipid-lowering treatment with
diet and pravastatin was also effective on TGF-beta1 pro-
duction in the monocytes of hypercholesterolemic patients.
Figure 3 reports, for each patient, an individual change in
TGF-beta1 production in the monocytes of hypercholester-
olemic patients before and after lipid-lowering treatment, as
evaluated by the mink-lung cells growth inhibition bioassay.
We found a 2.4-fold mean increase in TGF-beta1–
dependent biologic activity after pravastatin treatment, as
compared with the baseline values (at baseline: 3H-
thymidine incorporation: 4,400 500 cpm/well, which was
1.6  0.2 ng/ml on the standard curve; after pravastatin:
1,790  400 cpm/well, which was 3.8  0.9 ng/ml on the
standard curve; p  0.01).
To elucidate the possible mechanisms for changes in
monocyte TGF-beta1 production, we studied the effect of
pravastatin on in vitro TGF-beta1 production in monocytes
and its mRNA expression. Treatment with pravastatin
dose-dependently increases TGF-beta1 production from
4.5  1.0 to 9.5  3 ng/ml at 5 M (p  0.01, n  5). No
further significant increase was observed at 10 M. Co-
incubation of pravastatin (5 M) with mevalonate (100 M)
reversed the increase in TGF-beta1 production induced by
pravastatin (Fig. 4A). Figure 4B is a representative North-
ern blot analysis of TGF-beta1 mRNA expression from
human monocyte cultures with or without pravastatin
(5 M). Significant pravastatin-induced TGF-beta1
mRNA expression was observed after 24 h of incubation
time; this increase was prevented by 100 M of mevalonate.
A 2.3-fold mean increase was found after densitometric
analysis of three consecutive experiments.
DISCUSSION
Lipid-lowering therapy for cardiovascular disease is com-
mon, and all of the mechanisms responsible for the benefit
of statins remain to be defined (19). Our study focused on
the impact of statin therapy on the levels of TGF-beta1, a
growth factor/cytokine implicated in the regulation of
chronic inflammation and atherogenesis (2). Our study
shows that four to six weeks of lipid-lowering treatment
with pravastatin (40 mg/day) significantly increased TGF-
beta1 circulating levels, as compared with lipid-lowering
treatment with the AHA phase 1 diet. Ex vivo monocyte
production of TGF-beta1 was also increased after pravasta-
tin treatment. Finally, pravastatin induced a dose-
dependent increase in TGF-beta1 production and a signif-
icant increase in mRNA expression in in vitro cultures of
human monocytes. Thus, taken together, our observations
demonstrate a pravastatin-dependent upregulation of the
TGF-beta1 profile.
Comparison with previous studies. Knowledge of the
effect of statin treatment on TGF-beta1 expression is
limited. Contrasting results have been found in TGF-beta1
tissue expression after HMG-CoA reductase inhibitor
treatment. Kitahara et al. (32) demonstrated that HMG-
CoA reductase inhibition, which was able to suppress
balloon injury-induced neointimal thickening, was associ-
ated with an increase in vascular TGF-beta expression. In
contrast, other studies demonstrated that statins were able
to inhibit TGF-beta1 expression in diabetic rat glomeruli
and cultured rat mesangial cells (33,34). Park and Galper
(35) recently demonstrated, in embrionic chicken atrial
cells, in the absence of lipoproteins, that inhibition of the
cholesterol pathway by HMG-CoA reductase inhibitors
resulted in a coordinated upregulation of the expression of
TGF-beta1, its type II receptor and plasminogen activator
inhibitor-1 promoter activity (35). These findings seem to
be cell-type specific and associated with different in vitro
and animal experimental conditions.
Our data extend these findings by demonstrating the
effect of a HMG-CoA reductase inhibition on TGF-beta1
levels in hypercholesterolemic patients and in in vitro
human monocytes.
According to several other studies, the beneficial effects of
statins may not be related to their cholesterol-lowering
actions (36). We found that the magnitude of increase in
Figure 3. Production of transforming growth factor-beta1 (TGF-beta1) in
the monocytes of hypercholesterolemic patients (n  9) at baseline and
after four to six weeks of diet plus pravastatin (40 mg/day) treatment. A
conditioned medium of unstimulated cultures was collected after 24 h, and
the biologic activity of TGF-beta1 was evaluated after acidification for
mink-lung epithelial cell bioassay. Mink-lung cells respond to TGF-beta1
released in the culture medium, with a decrease in deoxyribonucleic acid
synthesis, as evaluated by 3H-thymidine incorporation. A comparison with
the standard curve and multiplication by the dilution factor (1:10) yielded
TGF-beta1 concentration (ng/ml) in the conditioned medium of monocyte
cultures.
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TGF-beta1 circulating levels observed after pravastatin did
not show any correlation with the magnitude of change in
total and LDL cholesterol levels. Furthermore, after adjust-
ment for age, gender and changes of lipid levels, TGF-beta1
concentrations were still significantly increased by pravasta-
tin, but not by diet alone.
HMG-CoA reductase inhibition and TGF-beta1. The
involvement of the melavonate pathway in the upregulation
of TGF-beta1 expression in human monocytes was demon-
strated by prevention of the stimulatory effect caused by
pravastatin, when mevalonate was simultaneously added to
pravastatin in the culture medium. We did not undertake
further studies to evaluate different branches of the choles-
terol metabolic pathway (37); however, previous studies
demonstrated that HMG-CoA reductase inhibitors may
upregulate TGF-beta signaling through a geranylgeranyla-
tion pathway (35).
The finding that HMG-CoA reductase inhibition is able
to induce an increase in the monocyte expression of TGF-
beta1 could have important implications for the mechanism
of action of these agents. TGF-beta1 showed a wide range
of activities on vascular and inflammatory cells, and may
have different functions during various stages of atheroscle-
rosis. In vitro and in vivo experimental studies demonstrated
a role of TGF-beta1 in vascular smooth muscle cell prolif-
eration, extracellular matrix synthesis and myointimal hy-
perplasia (38–41).
Recent studies demonstrated, in mice heterozygous for
the deletion of the TGF-beta1 gene, subjected to a
cholesterol-enriched diet, a significant inflammatory re-
sponse in the vascular wall, as compared with normal mice,
suggesting a TGF-beta1–dependent anti-inflammatory role
in the pathogenesis of vascular lipid inflammatory lesions
(42). In addition, in vitro studies showed a role of TGF-
beta1 in the control of LDL receptor expression on human
liver and vascular smooth muscle cells (43,44). Our data
cannot suggest any pathophysiologic implications for TGF-
beta1 upregulation induced by pravastatin. However, be-
cause some studies reported depressed, active TGF-beta1
levels among patients with advanced atherosclerosis (16,18),
and others demonstrated that a genetically induced defi-
ciency of TGF-beta1 in mice promotes atherosclerosis (42),
a possible beneficial contribution of the statin-dependent
TGF-beta1 increase could be suggested.
Conclusions. An increase in TGF-beta1 plasma levels and
monocyte production by lipid-lowering treatment with an
HMG-CoA reductase inhibitor is a novel biologic effect of
these compounds, which should be kept in mind to explain
their pharmacologic action. Our results seem to show that
the increase in TGF-beta1 is due to interference with the
mevalonic pathway, not related to a cholesterol-lowering
effect. Additional studies are necessary to clarify the patho-
physiologic consequences of TGF-beta pathway activation
after pravastatin treatment.
Figure 4. The effect of pravastatin (Prava) and mevalonate (MEV) on the
production and messenger ribonucleic acid (mRNA) levels of transforming
growth factor-beta1 (TGF-beta1). (A) Bioassay of TGF-beta1 activity in a
conditioned medium of monocyte cultures incubated with pravastatin
(1–10 M) or pravastatin (5 M) plus mevalonate (100 M). A condi-
tioned medium from the cultures was collected after 24 h and acidified for
mink-lung epithelial cell bioassay. Mink-lung cells respond to TGF-beta1
released in the culture medium, with a dose-dependent decrease in
deoxyribonucleic acid (DNA) synthesis, as evaluated by 3H-thymidine
incorporation. A comparison with the standard curve and multiplication by
the dilution factor (1:10) yielded a dose-dependent increase in the
TGF-beta1 concentration (ng/ml) in the conditioned medium of monocyte
cultures. Mevalonate reversed the TGF-beta1–dependent effect on mink-
lung cells. The results are expressed as the mean value  SD of three
independent experiments performed in triplicate. Comparisons among
treatment conditions were carried out by analysis of variance, followed by
Dunnett’s test. *p  0.05, **p  0.01 and p  NS versus untreated
(control) cells. (B) Representative Northern blot analysis of TGF-beta1 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA in human
peripheral blood monocytes after incubation with pravastatin (5 M) alone
or mevalonate (100 M) together with pravastatin (5 M). Mononuclear
cells were cultured 24 h in serum-free conditions. Total RNA (5 g per
lane) was electrophoresed on 1.5% formaldehyde agarose gels, transferred
to nitrocellulose and hybridized with 32P random primer-labeled TGF-
beta1 complementary DNA. The sizes of the transcripts were determined
by comparison with 28S and 18S ribosomal RNA. Molecular size markers
are shown on the left. Lane 1  untreated cells; lane 2  pravastatin-
treated cells; and lane 3  cell treated with pravastatin plus mevalonate.
Quantitative data obtained from imaging are expressed in arbitrary units.
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